IRO1 Antibody

What is IRE1 and what are its primary functions in cellular physiology?

IRE1 (Inositol-requiring enzyme 1) is a transmembrane protein with dual enzymatic activity, functioning as both a serine/threonine kinase and an endoribonuclease. It serves as a key sensor for the endoplasmic reticulum unfolded protein response (UPR). In unstressed cells, the endoplasmic reticulum luminal domain of IRE1 remains in an inactive monomeric state through binding to the ER chaperone HSPA5/BiP . When misfolded proteins accumulate in the ER, HSPA5/BiP dissociates from IRE1, allowing its luminal domain to homodimerize, which promotes autophosphorylation of the kinase domain and subsequent activation of the endoribonuclease activity . The endoribonuclease activity specifically targets XBP1 mRNA, excising 26 nucleotides to generate a spliced transcript that encodes a transcriptional activator protein . This activator upregulates expression of UPR target genes, helping cells adapt to ER stress .

What are the different isoforms of IRE1 and how do they differ functionally?

In metazoans, IRE1 exists in two primary isoforms: IRE1α/ERN1 and IRE1β/ERN2 . IRE1α is the most evolutionarily conserved ER membrane protein and regulates many cellular processes involving cell survival and cell death . The IRE1 gene was first identified in yeast during investigations of genes involved in inositol phospholipid metabolism, complementing a yeast mutant that required exogenous inositol for growth . While both isoforms are involved in the unfolded protein response, they exhibit tissue-specific expression patterns and may have distinct functional roles in different physiological contexts . IRE1α is more widely expressed and has been more extensively studied for its roles in various pathological conditions, including immune disorders and autoimmune diseases .

How is IRE1 activity regulated under normal and stress conditions?

Under normal physiological conditions, IRE1α activity is negatively regulated through binding of the ER chaperone protein BiP to IRE1α's ER luminal domain . During accumulation of misfolded proteins, BiP dissociates from IRE1α due to its higher affinity for misfolded proteins . This dissociation leads to self-association of IRE1α's luminal domain, causing IRE1α to dimerize and trans-autophosphorylate its cytoplasmic kinase domain . This conformational change activates the ribonuclease domain, which then becomes enzymatically active and forms higher-order oligomers . Recent research has also shown that misfolded proteins can directly bind to IRE1α and activate it through a similar mechanism . This activation leads to both the splicing of XBP1 mRNA and the degradation of other specific mRNAs through regulated IRE1-dependent decay (RIDD) .

What is the mechanism of IRE1α-mediated regulated IRE1-dependent decay (RIDD) and how does it differ from XBP1 splicing?

IRE1α activation not only results in XBP1 splicing but also causes the cleavage of other ER-localized mRNAs, cytosolic mRNAs, ribosomal RNA, and miRNAs, leading to their degradation through a process known as regulated IRE1-dependent decay (RIDD) . Unlike XBP1 splicing, which requires a specific double-loop structure in the mRNA, RIDD-mediated cleavage is sequence-specific but does not necessarily require this structural feature . RIDD functions to reduce ER stress by decreasing the influx of newly synthesized proteins into the ER and participates in various biological functions including glucose metabolism, inflammation, and apoptosis . Notably, RIDD becomes hyperactivated under conditions of XBP1 deficiency and can be implicated in both cell survival and death, depending on the tissue type and stress intensity . The cleaved mRNA fragments generated through RIDD can also trigger inflammatory responses, adding another layer of complexity to IRE1α's role in cellular physiology .

How does IRE1α contribute to cell death pathways during prolonged ER stress?

IRE1α can induce cell death pathways by activating various apoptosis-inducing molecules through both its endonuclease and kinase functions . This pro-apoptotic activity is highly regulated and depends on the level and type of stress as well as the tissue origin . While IRE1α activity is necessary for normal cellular functions and stress adaptation, when a threshold is reached in the balance between survival and death signals, IRE1α activates cell death signaling . This process is regulated by various partner molecules and involves interaction with a diverse hub of molecules through TNF receptor-associated factor 2 (TRAF2) . The IRE1α-TRAF2 association forms a complex with apoptosis signaling kinase 1 (ASK1) and phosphorylates c-Jun N-terminal kinase (JNK), triggering the intrinsic apoptosis pathway . Additionally, IRE1α can promote death receptor-independent caspase-8 activation through association with receptor-interacting serine/threonine protein kinase 1 (RIPK1), leading to activation of caspase-9 and caspase-3-mediated cell damage . Furthermore, the IRE1α/TRAF2 interaction promotes NFκB-dependent autocrine production of TNFα and apoptosis .

What is the role of IRE1α in autoimmune disease pathogenesis?

IRE1α plays significant roles in immune cell function and has been implicated in autoimmune disease pathogenesis through several mechanisms. Disturbances in the ER environment can result in abnormal post-translational modifications (PTM) of many proteins, which can then become neoantigens that activate autoimmune responses . Several ER proteins, including insulin, glucose-regulated protein 78 (GRP78), glutamic acid decarboxylase 65, and chromogranin A can become neoantigens due to abnormal PTM . These neoantigens activate autoreactive T-cells, leading to pathological conditions . For example, in rat insulinoma cells and non-obese diabetic mice, cytokine-induced ER stress produces post-translationally modified GRP78 or BiP . IRE1α's role in regulating cytokine production and inflammatory responses also contributes to autoimmune disease development. Understanding the specific mechanisms by which IRE1α contributes to different autoimmune conditions is an active area of research, with potential implications for developing targeted therapeutic strategies .

What are the key considerations for selecting appropriate IRE1 antibodies for specific experimental applications?

When selecting IRE1 antibodies for research, several critical factors must be considered. First, researchers should determine which IRE1 isoform (IRE1α/ERN1 or IRE1β/ERN2) is relevant to their study, as these require different antibodies with specific epitope recognition . Second, the intended application is crucial—different applications require antibodies with distinct properties. For example, the anti-IRE1 monoclonal antibody [9F2] (ab96481) is suitable for flow cytometry, western blotting, and immunohistochemistry on paraffin-embedded samples, but may not be appropriate for all experimental setups . Third, species reactivity must be considered—many IRE1 antibodies are validated for human samples but may not cross-react with rodent or other model organisms . Finally, researchers should verify the immunogen information; for instance, ab96481 was raised against a recombinant fragment within human ERN1 (amino acids 250-450) . This information helps predict whether the antibody will recognize specific domains or phosphorylation states of IRE1, which may be crucial depending on the research question.

How can researchers validate IRE1 antibody specificity and sensitivity for their experimental systems?

Validating IRE1 antibody specificity and sensitivity is essential for generating reliable research data. A comprehensive validation approach should include multiple complementary methods. First, western blot analysis using positive controls (cells known to express IRE1) and negative controls (IRE1 knockout cells or IRE1-negative cell lines) can confirm antibody specificity at the expected molecular weight . Second, immunoprecipitation followed by mass spectrometry can verify that the antibody is pulling down IRE1 specifically. Third, siRNA or CRISPR-mediated knockdown of IRE1 should result in reduced antibody signal if the antibody is specific . For phospho-specific IRE1 antibodies, treatment with lambda phosphatase can confirm specificity for the phosphorylated form. Additionally, researchers should compare results across multiple antibodies targeting different epitopes of IRE1 when possible. Finally, citation history can provide insight into antibody reliability—antibodies with multiple citations in peer-reviewed publications (such as ab96481 with 11 citations) often have established performance records .

What experimental conditions are optimal for detecting IRE1 activation in cellular stress models?

Detecting IRE1 activation requires careful optimization of experimental conditions. The timing of sample collection is critical, as IRE1 activation is dynamic—typically peaking 4-8 hours after stress induction, though this varies by cell type and stressor . Common ER stress inducers include tunicamycin (inhibits N-linked glycosylation), thapsigargin (disrupts calcium homeostasis), DTT (disrupts disulfide bonds), and palmitate (induces lipotoxicity), each with different optimal concentrations and treatment durations . When detecting IRE1 activation by immunoblotting, phosphorylation-dependent mobility shift can be observed, though phospho-specific antibodies provide more direct evidence of activation . XBP1 splicing assays offer a functional readout of IRE1 endonuclease activity—RT-PCR of XBP1 followed by restriction enzyme digestion or qPCR with primers spanning the splice junction can quantify spliced vs. unspliced XBP1 . For RIDD activity, measuring degradation of known RIDD targets by qPCR provides evidence of IRE1 activation. Finally, immunofluorescence microscopy can visualize IRE1 oligomerization as punctate structures, indicating activation, though this requires high-quality antibodies and careful fixation protocols .

How can IRE1 antibodies be utilized to investigate the role of UPR in autoimmune diseases?

IRE1 antibodies serve as valuable tools for investigating the unfolded protein response (UPR) in autoimmune disease contexts. Researchers can employ immunohistochemistry with IRE1 antibodies to examine IRE1 expression and localization in tissue samples from patients with autoimmune conditions, comparing them with healthy controls . Flow cytometry using IRE1 antibodies allows quantification of IRE1 expression levels in specific immune cell populations isolated from patients, revealing cell type-specific alterations in the UPR . Western blotting with phospho-specific IRE1 antibodies enables assessment of IRE1 activation status in patient-derived samples or animal models of autoimmune diseases . Co-immunoprecipitation experiments using IRE1 antibodies can identify disease-specific interaction partners that may contribute to pathogenesis . Additionally, chromatin immunoprecipitation (ChIP) assays using XBP1 antibodies (downstream of IRE1) can map the transcriptional targets affected by IRE1 activation in autoimmune conditions . These approaches can reveal how abnormal IRE1 activation contributes to the generation of neoantigens through post-translational modifications and the production of inflammatory cytokines, both of which are key mechanisms in autoimmune disease development .

What is the significance of IRE1α in immune cell function and how can antibodies help examine this relationship?

IRE1α plays critical roles in immune cell development, differentiation, and function, making IRE1 antibodies essential tools for immunological research. In B cells, IRE1α is necessary for plasma cell differentiation and antibody production—researchers can use IRE1 antibodies to track IRE1α expression and activation during B cell differentiation through immunoblotting and flow cytometry . For dendritic cells, IRE1α regulates antigen presentation and cytokine production—immunofluorescence with IRE1 antibodies can reveal its localization and activation status during dendritic cell maturation and interaction with T cells . In macrophages, IRE1α mediates inflammatory responses—antibodies against phosphorylated IRE1α can monitor its activation during macrophage polarization and response to pathogen-associated molecular patterns . For T cells, IRE1α influences differentiation into specific subsets—flow cytometry with IRE1 antibodies can identify IRE1α expression patterns in different T cell populations (Th1, Th2, Th17, Treg) . Importantly, comparing IRE1α activation in immune cells from healthy individuals versus autoimmune disease patients using phospho-specific antibodies can reveal disease-specific alterations in UPR signaling . Multi-parameter flow cytometry combining IRE1 antibodies with markers of immune cell activation provides insight into how ER stress and immune activation are coordinated during autoimmune responses .

How can IRE1 antibodies contribute to the development of therapeutic strategies targeting the UPR in disease?

IRE1 antibodies play crucial roles in developing and validating therapeutic strategies targeting the UPR in disease contexts. In preclinical research, antibodies are used to confirm target engagement of small molecule IRE1 inhibitors through immunoprecipitation followed by activity assays or by detecting changes in IRE1 phosphorylation status . For drug screening, cell-based assays utilizing IRE1 antibodies in high-content imaging or flow cytometry can identify compounds that modulate IRE1 activity or expression . In animal models, immunohistochemistry with IRE1 antibodies evaluates the tissue-specific effects of IRE1-targeted therapeutics . Importantly, phospho-specific IRE1 antibodies serve as pharmacodynamic biomarkers to assess inhibitor efficacy in both preclinical models and potentially in clinical samples . Additionally, antibodies against XBP1s (spliced XBP1) help determine the functional consequences of IRE1 inhibition on downstream signaling . Multiplex immunoassays combining IRE1 activation markers with disease-specific biomarkers can establish correlations between UPR modulation and disease outcomes . Finally, proximity ligation assays using IRE1 antibodies paired with antibodies against potential interacting proteins can reveal how therapeutic compounds disrupt specific protein-protein interactions within the IRE1 signaling complex .

What are the comparative detection capabilities of different IRE1 antibody assays and techniques?

Different techniques for IRE1 detection offer varying sensitivities and information content, as summarized in the following table:

When selecting an antibody like the Anti-IRE1 antibody [9F2] (ab96481), researchers should consider these performance characteristics across different applications . For instance, while this antibody performs well in flow cytometry, western blotting, and IHC-P with human samples, optimal dilutions and sample preparation protocols may vary across these applications . Validation through multiple techniques is recommended to ensure reliable results when studying IRE1 biology in different experimental contexts.

What are typical expression patterns of IRE1α in different tissues and how does this impact antibody selection?

IRE1α expression varies significantly across tissues, which has important implications for antibody selection and experimental design. The following table summarizes typical expression patterns and corresponding antibody considerations:

For the anti-IRE1 antibody [9F2] (ab96481), which recognizes amino acids 250-450 of human ERN1, tissues with high IRE1α expression typically yield stronger signals . In tissues with lower expression, signal amplification systems or more sensitive detection methods may be necessary . Additionally, researchers should be aware that IRE1α expression can be dramatically upregulated during ER stress conditions, potentially altering optimal antibody dilutions between basal and stressed states .

What are the long-term antibody detection capabilities and stability considerations for IRE1-related research?

Understanding antibody stability and detection longevity is crucial for experimental planning and data interpretation in IRE1-related research. Based on available data on antibody persistence in other systems, we can draw parallels for IRE1 antibody research:

For detection capabilities, studies on antibody persistence after infection provide useful insights. Research on SARS-CoV-2 antibodies shows that antibodies can be detected up to one year after infection, even in mild cases, with anti-N pan-Ig and anti-S IgG showing better persistence (82.7% and 84.6% detection rates at one year) compared to anti-S1 IgG (57.7%) . This suggests that antibodies targeting different epitopes have varying persistence profiles . By analogy, IRE1 antibodies targeting different domains may show different long-term detection capabilities. Importantly, while antibody titers may wane over time, detection is still possible in most cases (94.2%) when using multiple antibody types in combination . This highlights the importance of using complementary detection approaches in long-term IRE1 studies.